Correction: Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients (PLoS ONE (2014) 9, 2 (e89389) DOI: 10.1371/journal.pone.0089389);Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hung, Man Hsin ^a,b   Liu, Chun Yu ^a,b   Shiau, Cheng Ying ^a,b   Hsu, Chin Yi ^a,b   Tsai, Yi Fang ^a,b   Wang, Yu Ling ^a   Tai, Ling Chen ^a   King, Kuang Liang ^a,b   Chao, Ta Chung ^a,b   Chiu, Jen Hwey ^b   Su, Cheng Hsi ^b,c   Lo, Su Shun ^b   Tzeng, Cheng Hwai ^a,b   Shyr, Yi Ming ^a,b   Tseng, Ling Ming ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; TIME; TRIPLE NEGATIVE BREAST CANCER; BRAIN; BRAIN TUMOR; METABOLISM; PATHOLOGY; RISK; SECONDARY;

ADULT; AGE FACTORS; BRAIN; BRAIN NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84897823394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100460     Document Type: Erratum

References (31)

1. MayerM. (2007) A patient perspective on brain metastases in breast cancer. Clin Cancer Res 13: 1623-1624.
2. Benjamin L, Cotte FE, Mercier F, Vainchtock A, Vidal-Trécan G et al. (2012) Burden of breast cancer with brain metastasis: a French national hospital database analysis. J Med Econ 15: 493-499.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P et al. (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872. (Pubitemid 41079905)
4. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22: 3608-3617. (Pubitemid 41103668)
5. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F et al. (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45: 2792-2798.
6. Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A et al. (2011) Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22: 1571-1581.
7. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52: 2349-2354. (Pubitemid 14205961)
8. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC et al. (2004) Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 16: 345-349. (Pubitemid 38967255)
9. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B et al. (2009) Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 117: 297-303.
10. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW et al. (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101: 1760-1766. (Pubitemid 39314738)
11. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF et al. (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26: 2373-2378.
12. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747.
13. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Brest cancer, 2013 Verson I. Avalible: http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf.Accessed Febuary 28, 2013.
14. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ et al. (2008) Prognostic Significance of Nottingham Histologic grade in invastive breast carcinoma. J Clin Oncol 26: 3153-3158.
15. Beadle BM, Woodward WA, Buchholz TA. (2011) The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol 21: 26-34.
16. Isaiah JF. (2003)The Pathogenesis of Cancer Metastasis: the'seed and soil' hypothesis revisited. Nature reviews Cancer 3: 453-458.
17. Arvold ND, Taghian AG, Niemierko A, Abi Raad RE, Sreedhara M et al. (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29: 3885-3891.
18. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D et al. (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271-3277.
19. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK et al. (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6: 194.
20. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J et al. (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor- positive breast cancer? Lancet 355: 1869-1874. (Pubitemid 30311879)
21. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330.
22. Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM et al.(2009) Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276: 212-220.
23. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107: 696-704. (Pubitemid 44232661)
24. Niwinska A, Pogoda K, Murawska M, Niwiński P (2011) Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 37: 635-642.
25. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS et al. (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10: R20.
26. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K. et al. (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110: 2640-3647.
27. Niwinska A, Murawska M. (2012) New breast cancer recursive partitioning analysis prognostic index in patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 82: 2065-2071.
28. Marko NF, Xu Z, Gao T, Weil RJ (2012) Predicting survival in women with breast cancer and brain metastasis: A nomogram outperforms current survival prediction models. Cancer 118: 3749-3757.
29. College of American Pathologists (2012). Protocal for the Examination of Specimens From Patients with Invasive Carcinoma of the Breast. Avalible: http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2009/ InvasiveBreast-09protocol.pdf Accessd Febuary 18, 2013.
30. Miller K.D, Weathers T, Haney LG, Timmerman R, Dickler M, et al. (2003). Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol 14: 1072-77. (Pubitemid 36950171)
31. Kaplan MA, Inal A, Kucukoner M, Urakci Z, Ekici F, et al. (2013). Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients. Onkologie 36: 176-81.